Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma

Clin Cancer Res. 2023 Sep 22:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2292. Online ahead of print.ABSTRACTImmune-based approaches including T-cell redirection have transformed the therapeutic landscape in myeloma. Injection of dendritic cells (DC) led to the induction of immune responses in vaccinated patients with myeloma. These studies pave the way for future combination strategies harnessing DCs to enhance tumor immunity and improve outcomes in myeloma. See related article by Freeman et al., p. 000.PMID:37737650 | DOI:10.1158/1078-0432.CCR-23-2292
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research